Updated: January 12, 2026
How Does Ingrezza Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett

Summarize with AI
Ingrezza works by blocking VMAT2, a protein that regulates dopamine release. Here's a plain-English explanation of how Ingrezza reduces involuntary movements.
Ingrezza (valbenazine) is classified as a VMAT2 inhibitor — but what does that actually mean? And how does blocking a transporter protein in the brain translate to fewer involuntary movements? Here's the science, explained in plain language.
The Problem: Too Much Dopamine Signaling
To understand how Ingrezza works, you first need to understand what goes wrong in tardive dyskinesia (TD) and Huntington's disease chorea.
Dopamine is a neurotransmitter — a chemical messenger in your brain. It plays a key role in movement control, emotion, and reward. In the motor areas of the brain, dopamine normally helps coordinate smooth, purposeful movements.
In tardive dyskinesia, chronic use of antipsychotic drugs (which block dopamine receptors) can cause dopamine receptors to become hypersensitive — they start overreacting to dopamine. When dopamine floods into the synapse, these hypersensitive receptors fire too strongly and too often, creating the jerky, uncontrolled movements of TD.
In Huntington's disease, neurodegeneration disrupts the normal balance of dopamine and other neurotransmitters in the brain's movement control circuits — causing the uncontrollable movements (chorea) that characterize the disease.
The Solution: Ingrezza's VMAT2 Inhibition
VMAT2 stands for Vesicular Monoamine Transporter 2. Think of VMAT2 as a pump inside dopamine-producing nerve cells. Its job is to load dopamine molecules from inside the cell into tiny storage containers called vesicles. These vesicles then travel to the end of the nerve cell, waiting to release dopamine into the synapse when the cell fires.
Valbenazine (the active ingredient in Ingrezza) blocks this VMAT2 pump. When the pump is blocked:
Less dopamine gets loaded into vesicles.
Less dopamine is available for release into the synapse.
The dopamine receptors (even hypersensitive ones) receive fewer signals.
Abnormal movements diminish.
Why Is Ingrezza's VMAT2 Selectivity Important?
Ingrezza (valbenazine) is highly selective for VMAT2 over other targets. It has essentially no significant activity at dopamine, serotonin, norepinephrine, or other monoamine receptors. This selectivity is what distinguishes it from older medications like tetrabenazine, which act on additional receptors and cause more side effects (like depression and parkinsonism).
VMAT2 also transports norepinephrine, serotonin, and histamine — but in much smaller amounts compared to dopamine in the areas of the brain affected by TD and HD chorea. Ingrezza's selectivity for VMAT2 (versus VMAT1, which is found outside the brain) means it targets dopamine release in the brain without significantly affecting peripheral tissues.
The Active Metabolite: How Ingrezza Works in Your Body
Valbenazine is what pharmacologists call a prodrug — it is converted in the body to its active form. After you take Ingrezza, your body converts valbenazine into an active metabolite called [+]-alpha-dihydrotetrabenazine ([+]-alpha-HTBZ). This metabolite is the form that actually does most of the VMAT2 blocking. It reaches peak levels in the blood 4–8 hours after taking Ingrezza. This is different from older tetrabenazine, which produces a racemic (mixed) mixture of active forms — Ingrezza's prodrug approach allows for a purer, more controlled pharmacological effect.
Does Ingrezza Cure Tardive Dyskinesia or Huntington's Disease?
No. Ingrezza controls the symptoms of TD and HD chorea but does not cure the underlying conditions. If Ingrezza is stopped, involuntary movements typically return. For many patients, Ingrezza is a long-term treatment. Some patients with TD may see partial recovery of receptors over time if the offending antipsychotic is reduced or changed, but TD can be permanent in some cases.
For a broader overview of Ingrezza including dosage and approval information, see: What Is Ingrezza? Uses, Dosage, and What You Need to Know.
If you've been prescribed Ingrezza and need help finding a pharmacy that can fill it, medfinder locates pharmacies near you without you having to make multiple calls.
Frequently Asked Questions
Ingrezza (valbenazine) blocks a protein called VMAT2 (vesicular monoamine transporter 2) in dopamine-producing nerve cells. This reduces the amount of dopamine loaded into storage vesicles, which in turn reduces dopamine release into the synapse. Less dopamine signaling means fewer abnormal movements, because in tardive dyskinesia and HD chorea, excess or dysregulated dopamine signaling drives the uncontrolled movements.
Ingrezza (valbenazine) is more selective for VMAT2 than tetrabenazine (Xenazine). Tetrabenazine acts on multiple targets including dopamine D2 receptors, which can cause depression, parkinsonism, and sedation at higher rates. Ingrezza's high VMAT2 selectivity and once-daily dosing make it easier to use with a more predictable side effect profile.
A VMAT2 inhibitor is a drug that blocks the vesicular monoamine transporter 2 protein in nerve cells. VMAT2 normally loads neurotransmitters (primarily dopamine) from the cell body into vesicles for release. When VMAT2 is blocked, less dopamine is released into the synapse. VMAT2 inhibitors are used to treat movement disorders driven by excess dopamine signaling.
Valbenazine reaches peak plasma concentration about 0.5–1 hour after taking it. Its active metabolite ([+]-alpha-HTBZ) peaks 4–8 hours after dosing. Steady-state blood levels are reached within about 1 week of daily dosing. The half-life allows for once-daily dosing. After stopping Ingrezza, it takes several days for the drug and its metabolite to fully clear the system.
For most patients, yes — tardive dyskinesia symptoms return when Ingrezza is stopped because the drug controls symptoms without curing the underlying condition. Some patients may see partial long-term improvement in TD over time, especially if the causative antipsychotic is also adjusted. Any decision to stop Ingrezza should be made with your doctor.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Ingrezza also looked for:
More about Ingrezza
31,889 have already found their meds with Medfinder.
Start your search today.





